SHARE is an easy-to-search, real-time repository of HIV-related systematic reviews. Whether you’re a researcher, community member, healthcare provider or policymaker, SHARE provides a ‘one-stop shop’ for HIV-related information that has been published through a systematic review.

BACKGROUND: Women living with human immunodeficiency virus (HIV) experience significant psychological burdens due to biological and gendered factors such as pregnancy, childbirth and breastfeeding. However, a life course-based understanding of...

Objective: To map the literature on the development and evaluation of the knowledge, skills, and attitudes of pharmacy students concerning the care of people living with HIV (PLHIV). Method: A scoping review...

Introduction Tuberculosis is a leading infectious cause of death and morbidity in people with and without HIV. Better identification of severe forms could help target early interventions to reduce mortality...

BACKGROUND: Demand for a future HIV vaccine, similar to other vaccines, is vulnerable to misinformation. A number of studies have examined HIV vaccine acceptability and demand, but few have systematically...

Co-infection of HIV and HBV is still a major global public health concern. Co-infected people have a nearly threefold increased risk of end-stage liver disease, with a noticeably faster development...

Introduction: Fundamental progress has been made in HIV care, and one of the major advances was the implementation of Differentiated Service Delivery (DSD) models. DSD models are important in reducing cost...

Key take-home messages

BACKGROUND: HIV/AIDS continues to pose a significant global health challenge, especially in low- and middle-income countries. Economic evaluations are essential to identify cost-effective prevention strategies and allocate limited healthcare resources...

BACKGROUND: The HIV epidemic in Africa is still a serious public health concern, particularly for children who are more vulnerable to its negative consequences. Various studies carried out in different...

Background: Dolutegravir (DTG) + lamivudine (3TC) has demonstrated efficacy and safety in phase 3 clinical trials; however, most published data are from people with HIV-1 in North America and Europe. Methods: To...

Older women living with HIV are uniquely situated at multiple marginalized intersections because of their gender, age, and HIV status. However, research into how gender-based stigma (GBS) affects HIV prevention...

Despite proven efficacy in preventing human immunodeficiency virus (HIV) transmission, pre-exposure prophylaxis (PrEP) remains underutilized among adolescents and young adults (AYA) in the United States (US). This systematic review and...